Skip to main content
    D

    DexCom Inc (DXCM)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $82.04
    +0.43 (+0.53%)

    Market Cap: $30.44B

    Last updated: Nov 17, 2026 at 4:39 PM ET

    DexCom Inc (DXCM) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    DexCom (DXCM) has a market cap of $30.44B and an enterprise value of $30.72B. Its trailing P/E of 30.7x is below its 5-year median of 67.5x. Its share count is down 4.19% from a year earlier.

    Total Valuation

    Enterprise value is 0.93% above the market cap, as debt exceeds cash.

    Market Cap$30.44B
    Enterprise Value$30.72B
    Latest price (Nov 17, 2026)$82.04

    Key Dates

    The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 10, 2027 (expected)
    Last Earnings DateOct 29, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 1.96% in the quarter ended Sep 30, 2026 and shrank 2.50% a year over 2 years.

    Shares Outstanding374.70M
    Shares Change (YoY)-4.19%
    Shares Change (QoQ)-1.96%
    Share Count Growth (2Y CAGR)-2.50%

    Valuation Ratios

    Sales and book value multiples are 6.0x and 12.1x. Its year-end P/E ranged from 31.8x to 374.4x from 2018 to 2025.

    P/E Ratio30.7x
    Forward P/E29.7x
    P/S Ratio6.0x
    Forward P/S5.8x
    P/B Ratio12.1x
    P/TBV Ratio12.7x
    P/FCF Ratio28.0x
    P/OCF Ratio21.5x
    PEG Ratio1.6

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 20.2x EBITDA and 28.2x free cash flow.

    EV / Earnings31.0x
    EV / Sales6.0x
    EV / EBITDA20.2x
    EV / EBIT24.3x
    EV / FCF28.2x

    Price Statistics

    The stock is up 41.30% over 52 weeks and trades 2.47% below its 50-day average.

    Beta (1Y)0.74
    52-Week Change+41.30%
    1-Month Change-4.58%
    3-Month Change-8.72%
    6-Month Change+22.54%
    5-Year Change-47.18%
    10-Year Change+320.71%
    Total Return (1Y)+41.30%
    Total Return (3Y CAGR)-7.89%
    Total Return (5Y CAGR)-12.74%
    Return vs SPY (1Y)+24.79%
    Max Drawdown (1Y)-22.61%
    Max Drawdown (3Y)-60.95%
    Sharpe Ratio (1Y)0.83
    Correlation with SPY (1Y)0.27
    50-Day Average$84.12
    200-Day Average$75.17
    52-Week Range$56.72 to $92.59
    RSI (14 Days)48.8
    Average Volume (20 Days)5.20M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.74x current liabilities, and total debt is 0.49x shareholder equity.

    Current Ratio1.74x
    Quick Ratio1.40x
    Debt / Equity0.49x
    Debt / EBITDA0.81x
    Debt / FCF1.13x

    Returns and Efficiency

    Return on invested capital is 26.22% over the last 12 months, against a 5-year average of 11.88%.

    Return on Equity (ROE)39.09%
    Return on Assets (ROA)15.88%
    Return on Invested Capital (ROIC)26.22%
    Return on Capital Employed (ROCE)31.67%
    ROE (5Y Average)22.13%
    ROA (5Y Average)8.29%
    ROIC (5Y Average)11.88%
    Asset Turnover0.74x
    Inventory Turnover2.49x
    Receivables Turnover4.18x
    Cash Conversion Cycle-182 days

    Taxes

    Income tax took 21.50% of pretax income over the last 12 months.

    Income Tax (TTM)$271.40M
    Effective Tax Rate21.50%

    Scores

    DXCM has an Altman Z-Score of 7.49, in the safe zone above 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.

    Altman Z-Score7.49
    Altman Z ZoneSafe
    Piotroski F-Score7 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $5.10B over the last 12 months is up 13.03% from the 12 months before.

    Revenue$5.10B
    Revenue Growth (YoY)+13.03%
    Gross Profit$3.24B
    Operating Income$1.22B
    Pretax Income$1.26B
    Net Income$991.00M
    EBITDA$1.54B
    EBIT$1.26B
    Reported EPS (TTM)$2.67

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 40.71% of the $6.24B in total assets.

    Cash and Equivalents$961.40M
    Total Debt$1.24B
    Net Debt$282.30M
    Net Debt Per Share$0.75
    Working Capital$1.66B
    Shareholder Equity$2.54B
    Book Value Per Share$6.77
    Tangible Book Value$2.42B
    Tangible Book Per Share$6.46
    Total Assets$6.24B
    Total Liabilities$3.70B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $316.10M of capital spending, operating cash flow left $1.10B of free cash flow.

    Operating Cash Flow$1.41B
    Capital Expenditures$316.10M
    Free Cash Flow$1.10B
    FCF Per Share$2.91
    Depreciation and Amortization$275.00M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 23.98%, against a 5-year average of 15.05%.

    Gross Margin63.42%
    Operating Margin23.98%
    Pretax Margin24.73%
    Net Margin19.41%
    EBITDA Margin30.12%
    EBIT Margin24.73%
    FCF Margin21.52%
    Gross Margin (5Y Average)63.42%
    Operating Margin (5Y Average)15.05%
    Net Margin (5Y Average)13.55%

    Growth

    Revenue grew 17.01% a year over 3 years, and EPS 33.93% a year.

    Revenue Growth (3Y CAGR)+17.01%
    Revenue Growth (5Y CAGR)+19.33%
    EPS Growth (3Y CAGR)+33.93%
    EPS Growth (5Y CAGR)+21.79%
    FCF Growth (3Y CAGR)+52.34%
    FCF Growth (5Y CAGR)+31.25%
    Operating Income Growth (3Y CAGR)+32.59%
    Book Value Per Share Growth (2Y CAGR)+17.65%
    Tangible Book Per Share Growth (2Y CAGR)+20.33%

    Revenue and profit by year

    Dividends and Yields

    DXCM does not pay a dividend. Its free cash flow yield is 3.57%.

    Earnings Yield3.26%
    FCF Yield3.57%
    Buyback Yield2.24%
    Shareholder Yield2.24%

    Stock Splits

    The last split was a 4-for-1 forward split on Jun 13, 2022.

    Last Split DateJun 13, 2022
    Split TypeForward split
    Split Ratio4:1

    Peer Position

    Against 8 similar companies, DXCM has the 3rd highest P/E.

    P/E Ratio30.7x vs 19.3x median
    P/S Ratio6.0x vs 3.0x median
    ROIC26.22% vs 7.71% median
    Revenue Growth (Trailing 4 Quarters, YoY)+13.03% vs +8.87% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 11.30% and EPS growth at 22.47% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+11.30%
    EPS Growth Forecast (2Y CAGR)+22.47%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About DXCM

    What is DXCM's market cap?

    DexCom has a market cap of $30.44B. Its enterprise value, which adds debt and subtracts cash, is $30.72B.

    What is DXCM's P/E ratio?

    DexCom has a trailing P/E ratio of 30.7x and a forward P/E of 29.7x.

    How many shares of DXCM are outstanding?

    DexCom has 374.70M shares outstanding. The count is down 4.19% from a year earlier.

    Does DXCM pay a dividend?

    No. DexCom does not pay a dividend.

    How much debt does DXCM have?

    DexCom has $1.24B of total debt and $961.40M of cash and equivalents, a net debt position of $282.30M.